抗精神病药维持治疗预防精神分裂症复发的剂量探讨:一项Meta分析
该Meta分析纳入26项随机临床试验共4776例稳定期精神分裂症患者,分析72个剂量组。结果显示,预防复发的疗效在利培酮等效剂量约5 mg/d内快速提升,此后趋于平台;而因不良事件停药风险随剂量继续增加。缓解期患者约2.5 mg/d即达平台,提示个体化剂量需权衡疗效与耐受性。
要点
- 利培酮等效剂量约5 mg/d以上,额外获益有限而不良事件风险增加。
- 缓解期患者约2.5 mg/d等效剂量可能已足够,但再减量复发风险可能不成比例升高。
- 剂量反应为群体平均,代谢速度、年龄、病期、共病及药物相互作用需个体化调整。
核心结论
- 高于约5 mg/d利培酮等效剂量的抗精神病药对预防复发额外获益有限,且不良事件更多。
- 缓解期或使用高效价第一代抗精神病药者,低至2.5 mg/d利培酮等效剂量可能已足够。
- 低剂量端进一步减量可能伴随不成比例升高的复发风险,需谨慎。
- 观察结果为群体平均,个体剂量需结合代谢、年龄、病期、共病及药物相互作用调整。
研究设计与样本
- 系统检索Cochrane精神分裂症组试验注册库(2020年3月9日)、PubMed(2021年1月1日)及既往综述,并联系作者或药企补充信息。
- 两位评价者独立筛选比较固定剂量第二代抗精神病药、氟哌啶醇或氟奋乃静预防稳定期精神分裂症复发的随机临床试验。
- 按PRISMA指南双人提取数据,采用频率学剂量反应随机效应Meta分析。
- 共纳入26项研究、72个剂量组、4776例受试者。
主要发现
- 疗效相关剂量反应曲线呈双曲线形,利培酮等效剂量至5 mg/d时复发概率快速下降(相对复发风险0.43,95%CI 0.31-0.57;PANSS总分降低标准化均数差-0.55,95%CI -0.68至-0.41),此后趋于平坦。
- 因不良事件脱落风险在5 mg/d以上持续增加(5 mg/d相对风险1.38,95%CI 0.87-2.55;15 mg/d相对风险2.68,95%CI 1.49-4.62)。
- 缓解期患者亚组分析中,平台期更早出现,约在2.5 mg/d利培酮等效剂量。
关键数值与推荐
- 主要结局为研究定义的复发;次要结局包括再住院、PANSS或BPRS总分较基线降低、全因停药及因不良事件脱落。
- 疗效平台约在5 mg/d利培酮等效剂量,缓解期患者平台约在2.5 mg/d。
- 因不良事件脱落相对风险:5 mg/d为1.38(95%CI 0.87-2.55),15 mg/d为2.68(95%CI 1.49-4.62)。
临床怎么用
- 稳定期精神分裂症维持治疗可考虑利培酮等效剂量约5 mg/d,高于此剂量需评估额外获益与不良事件风险。
- 缓解期患者或使用高效价第一代抗精神病药者,可考虑低至2.5 mg/d利培酮等效剂量,但需监测复发风险。
- 剂量调整应个体化,综合考虑代谢速度、年龄、病期、共病及药物相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The doses of antipsychotic drugs needed for relapse prevention in schizophrenia is a debated issue. OBJECTIVE: To examine dose-response findings in a meta-analysis of randomized clinical trials. DATA SOURCES: Studies were identified through the Cochrane Schizophrenia Group's Study-Based Register of Trials (March 9, 2020), PubMed (January 1, 2021), and previous reviews. First authors and/or pharmaceutical companies were contacted for additional information. STUDY SELECTION: Two reviewers independently selected randomized clinical trials that compared fixed doses of a second-generation antipsychotic, haloperidol, or fluphenazine for relapse prevention in patients with stable schizophrenia. DATA EXTRACTION AND SYNTHESIS: Using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guideline, all parameters in duplicate were extracted and frequentist dose-response random-effects meta-analyses were conducted. MAIN OUTCOMES AND MEASURES: Study-defined relapse (primary outcome), rehospitalization, Positive and Negative Syndrome Scale or Brief Psychiatric Rating Scale total score reduction from baseline, all-cause discontinuation, and dropouts due to adverse events. RESULTS: Evidence from 72 dose arms from 26 studies with 4776 participants was analyzed. The efficacy-related dose-response curves had a hyperbolic shape meaning that the probability to relapse decreased rapidly with doses of up to 5-mg/d risperidone equivalent (relative relapse risk, 0.43; 95% CI, 0.31-0.57; standardized mean difference for Positive and Negative Syndrome Scale total score reduction, -0.55; 95% CI, -0.68 to -0.41), but flattened thereafter. In contrast, dropouts due to adverse events continued to increase beyond this dose (relative risk at 5 mg/d, 1.38; 95% CI, 0.87-2.55; relative risk at 15 mg/d, 2.68; 95% CI, 1.49-4.62). In a subgroup analysis of patients in remission, a plateau was reached earlier, at approximately 2.5-mg/d risperidone equivalent. CONCLUSIONS AND RELEVANCE: The findings of this meta-analysis suggest that doses higher than approximately 5-mg/d risperidone equivalent may provide limited additional benefit for relapse prevention but more adverse events. For patients in remission or who are receiving high-potency first-generation antipsychotics, doses as low as 2.5-mg/d risperidone equivalent may be sufficient. However, caution is needed at this low dose end when further decreases of dose may be accompanied by a disproportionally higher relapse risk. Moreover, the observations are averages, and factors such as slow or rapid metabolism, age, illness stage, comorbidities, and drug-drug interactions suggest that individual patients will often need higher or lower doses.
引用
- Leucht S, Bauer S, Siafis S, et al. Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis. JAMA Psychiatry. 2021. PMID: 34406325. doi:10.1001/jamapsychiatry.2021.2130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。